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Editorial Comment
Silent Left Ventricular
Dysfunction During Dipyridamole
Echocardiography: A New
Prognostic Marker*
PETER F. COHN, MD, FACC
Stony Brook, New York
The study by Bolognese et al. (I) in this issue of the Journal
has several important aspects including I) use of dipyrido-
mole as an ischemia-inducing agent, 2) documentation of
echocardiographic wall motion abnormalities as evidence of
myocardial ischemia, and 3) a comparison of prognosis in
patients with silent versus symptomatic episodes of myocar-
dial ischemia
. Although these three features are not unique
in themselves, their combination in one study is unusual .
Each merits comment in its own right, but it is the clinical
implications of this combination that are of most interest .
Dipyridamole echocardiography . The Italian investiga-
tors from Novarra have been pioneers in the use of dipyrid-
amole echocardiography and have employed it in a variety of
settings in patients with coronary artery disease (2,3), espe-
cially in the postinfarction period
(4,5) . Their colleagues in
Pisa have also used this technique (6 .7) . To employ a
pharmacologic rather than a physiologic stress in coronary
patients is not new . For example, the dipyridamole-thallium
tea enjoys wide popularity in those patients not deemed
sui'iabte for exercise testing because of concomitant periph-
ery vascular disease, infirmity or other causes
(9),
ischemia-induced wall motion abnormalities have long
been known to be associated with coronary artery disease
when precipitated by exercise (usually isotonic) and have
been documented noninvasively by radionuclide ventricu-
lography and echocardiography . More recently, dipyrida-
mole echocardiography has been used to precipitate and
document left ventricular dysfunction .
The present study . The current study (1) carves previous
work one step further by evaluating how often these hemo-
dynamic abnormalities were associated with angina and the
prognostic implications of such findings . Because left ven-
tricular function abnormalities appear early in the sequence
of events in the ischemic cascade . i t is not surprising that of
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the 128 patients who c :!hibited wall motion abnormalities
during dipyridamole infusion, only 80% had concomitant
ST segment changes . Angina] pain is the lost event in
this sequence anti was present in only 34 (27%) of the
128 patients . Therefore, as the investigators note (1),
.
studies that relied solely on [electrocardiographic]
criteria have probably greatly underestimated the number of
patients with silent ischemia ."
The adverse prognostic implications associated with thal-
lium scintigraphic abnormalities due to pharmacologically
induced ischemia are well known (9). The present study
reports that only 10% of patients with a negative dipyrida-
mole cehocardiographic response had subsequent cardiac
clinical events (unstable angina, reinfaretinn or death) com-
pared with 32% of those with ischemia-induced wall motion
abnormalities (p < 0 .05). When the prevalence rates in the
patients with and without angina during the test were com-
pared, the prognostic data were the same : 32% of both
groups had subsequent cardiac clinical events .
Because the coronary angiographic markers (number and
extent of the vascular lesions) in both groups were also the
same, the investigators (I) concluded that there was a similar
.mount of jeopardized myocardium in both groups of pa-
tients . This additional finding is important because it pro-
vides more data to a still controversial area. However, there
now appears to be a consensus that there are similarities in
the amount of jeopardized myocardium in silent and painful
ischemia, at least in regard to myocardial perfusion imaging
and left ventricular function studies, with only a few excep-
tions (10) .
Clinical implications. The present study reemphasizes
the prognostic importance of silent ischemia but also
stresses the importance of left ventricular dysfunction as a
reliable marker of both ischemia-induced hemodynamic ab-
normalities and prognosis . The investigators chose echocar-
diography as the procedure of choice, but radiunuclide
angiography also lends itself to such studies whether cor-
ventional techniques are used or newer ones, such as th
.:
nuclear VEST (II), are employed . The substitut(
.r of d
pharmacologic agent (whether dipyridamole or agents such
as adenosine or dobutamine) for the exercise test has certain
advantages in many patients and the impressive number of
echocardiographic abnormalities documented by the inves-
tigators, as well as their adverse prognostic influence, attests
to the value of this approach
. It is a safe prediction that we
will see further use of this type of technique in the evaluation
of patients with coronary artery disease, especially in those
who have had a myocardial infarction .
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